4.38
0.10 (2.34%)
| Penutupan Terdahulu | 4.28 |
| Buka | 4.26 |
| Jumlah Dagangan | 321,668 |
| Purata Dagangan (3B) | 595,781 |
| Modal Pasaran | 233,164,880 |
| Harga / Buku (P/B) | 6.68 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 17 Mar 2026 |
| EPS Cair (TTM) | -1.35 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 96.90% |
| Nisbah Semasa (MRQ) | 3.51 |
| Aliran Tunai Operasi (OCF TTM) | -35.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.11 M |
| Pulangan Atas Aset (ROA TTM) | -59.02% |
| Pulangan Atas Ekuiti (ROE TTM) | -154.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Achieve Life Sciences, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 9.69% |
| % Dimiliki oleh Institusi | 41.59% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Propel Bio Management, Llc | 31 Dec 2025 | 3,786,425 |
| Simplify Asset Management Inc. | 31 Dec 2025 | 1,184,512 |
| Kvp Capital Advisors, Lp | 31 Dec 2025 | 462,355 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 30 Jan 2026 | Pengumuman | Achieve Life Sciences Announced Granting of New Hire Inducement Awards |
| 12 Jan 2026 | Pengumuman | Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer |
| 17 Dec 2025 | Pengumuman | Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |